Literature DB >> 25201222

Costeff syndrome: clinical features and natural history.

Gilad Yahalom1, Yair Anikster, Ruth Huna-Baron, Chen Hoffmann, Lubov Blumkin, Dorit Lev, Rakefet Tsabari, Zeev Nitsan, Sheera F Lerman, Bruria Ben-Zeev, Ben Pode-Shakked, Shira Sofer, Avraham Schweiger, Tally Lerman-Sagie, Sharon Hassin-Baer.   

Abstract

Costeff syndrome (CS) is a rare autosomal-recessive neurological disorder, which is known almost exclusively in patients of Iraqi Jewish descent, manifesting in childhood with optic atrophy, ataxia, chorea and spastic paraparesis. Our aim was to study the clinical spectrum of CS and natural history using a cross-sectional study design. Consecutive patients with CS were recruited to the study. Patients were diagnosed based on clinical features, along with elevated urinary levels of methylglutaconic and methylglutaric acid, and by identification of the disease-causing mutation in the OPA3 gene in most. All patients were examined by a neurologist and signs and symptoms were rated. 28 patients with CS (16 males, 21 families, age at last observation 28.6 ± 16.1 years, range 0.5-68 years) were included. First signs of neurological deficit appeared in infancy or early childhood, with delayed motor milestones, choreiform movements, ataxia and visual disturbances. Ataxia and chorea were the dominant motor features in childhood, but varied in severity among patients and did not seem to worsen with age. Pyramidal dysfunction appeared later and progressed with age (r = 0.71, p < 0.001) leading to spastic paraparesis and marked gait impairment. The course of neurological deterioration was slow and the majority of patients could still walk beyond the fifth decade. While visual acuity seemed to deteriorate, it did not correlate with age. CS is a rare neurogenetic disorder that causes serious disability and worsens with age. Spasticity significantly increases over the years and is the most crucial determinant of neurological dysfunction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201222     DOI: 10.1007/s00415-014-7481-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A.

Authors:  Stephan Züchner; Irina V Mersiyanova; Maria Muglia; Nisrine Bissar-Tadmouri; Julie Rochelle; Elena L Dadali; Mario Zappia; Eva Nelis; Alessandra Patitucci; Jan Senderek; Yesim Parman; Oleg Evgrafov; Peter De Jonghe; Yuji Takahashi; Shoij Tsuji; Margaret A Pericak-Vance; Aldo Quattrone; Esra Battaloglu; Alexander V Polyakov; Vincent Timmerman; J Michael Schröder; Jeffery M Vance; Esra Battologlu
Journal:  Nat Genet       Date:  2004-04-04       Impact factor: 38.330

2.  Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews.

Authors:  Y Anikster; R Kleta; A Shaag; W A Gahl; O Elpeleg
Journal:  Am J Hum Genet       Date:  2001-10-19       Impact factor: 11.025

3.  3-Methylglutaconic aciduria: a new variant.

Authors:  A Zeharia; O N Elpeleg; M Mukamel; R Weitz; R Ariel; M Mimouni
Journal:  Pediatrics       Date:  1992-06       Impact factor: 7.124

4.  Barth syndrome may be due to an acyltransferase deficiency.

Authors:  A F Neuwald
Journal:  Curr Biol       Date:  1997-08-01       Impact factor: 10.834

5.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Authors:  S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner
Journal:  N Engl J Med       Date:  1983-01-27       Impact factor: 91.245

Review 6.  Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature.

Authors:  Saskia B Wortmann; Marinus Duran; Yair Anikster; Peter G Barth; Wolfgang Sperl; Johannes Zschocke; Eva Morava; Ron A Wevers
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

7.  Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition.

Authors:  K M Davey; J S Parboosingh; D R McLeod; A Chan; R Casey; P Ferreira; F F Snyder; P J Bridge; F P Bernier
Journal:  J Med Genet       Date:  2005-07-31       Impact factor: 6.318

Review 8.  Neuroimaging of mitochondrial disease.

Authors:  Russell P Saneto; Seth D Friedman; Dennis W W Shaw
Journal:  Mitochondrion       Date:  2008-05-23       Impact factor: 4.160

9.  3-Methylglutaconic aciduria in the Iraqi-Jewish 'optic atrophy plus' (Costeff) syndrome.

Authors:  O N Elpeleg; H Costeff; A Joseph; Y Shental; R Weitz; K M Gibson
Journal:  Dev Med Child Neurol       Date:  1994-02       Impact factor: 5.449

10.  Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease.

Authors:  Francis G Blankenberg; Stephen L Kinsman; Bruce H Cohen; Michael L Goris; Kenneth M Spicer; Susan L Perlman; Elliot J Krane; Viktoria Kheifets; Martin Thoolen; Guy Miller; Gregory M Enns
Journal:  Mol Genet Metab       Date:  2012-09-28       Impact factor: 4.797

View more
  6 in total

Review 1.  Mitochondrial Membrane Dynamics and Inherited Optic Neuropathies.

Authors:  Eleni Bagli; Anastasia K Zikou; Niki Agnantis; Georgios Kitsos
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 2.  Importance of lipids for upper motor neuron health and disease.

Authors:  Aksu Gunay; Heather H Shin; Oge Gozutok; Mukesh Gautam; P Hande Ozdinler
Journal:  Semin Cell Dev Biol       Date:  2020-12-13       Impact factor: 7.727

3.  Disrupted mitochondrial function in the Opa3L122P mouse model for Costeff Syndrome impairs skeletal integrity.

Authors:  Alice E Navein; Esther J Cooke; Jennifer R Davies; Terence G Smith; Lois H M Wells; Atsushi Ohazama; Christopher Healy; Paul T Sharpe; Sam L Evans; Bronwen A J Evans; Marcela Votruba; Timothy Wells
Journal:  Hum Mol Genet       Date:  2016-04-22       Impact factor: 6.150

4.  Optic atrophy, cataracts, lipodystrophy/lipoatrophy, and peripheral neuropathy caused by a de novo OPA3 mutation.

Authors:  Stephanie C Bourne; Katelin N Townsend; Casper Shyr; Allison Matthews; Scott A Lear; Raj Attariwala; Anna Lehman; Wyeth W Wasserman; Clara van Karnebeek; Graham Sinclair; Hilary Vallance; William T Gibson
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-01

5.  Autosomal dominant optic atrophy and cataract "plus" phenotype including axonal neuropathy.

Authors:  Alejandro Horga; Enrico Bugiardini; Andreea Manole; Fion Bremner; Zane Jaunmuktane; Lois Dankwa; Adriana P Rebelo; Catherine E Woodward; Iain P Hargreaves; Andrea Cortese; Alan M Pittman; Sebastian Brandner; James M Polke; Robert D S Pitceathly; Stephan Züchner; Michael G Hanna; Steven S Scherer; Henry Houlden; Mary M Reilly
Journal:  Neurol Genet       Date:  2019-04-01

Review 6.  Hereditary Optic Neuropathies: Induced Pluripotent Stem Cell-Based 2D/3D Approaches.

Authors:  Marta García-López; Joaquín Arenas; M Esther Gallardo
Journal:  Genes (Basel)       Date:  2021-01-18       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.